pembrolizumab,patritumab,amivantamab
amgen,janssen,daiichi sankyo,merck
['pembro', 'key,note,789', 'sclc', 'patritumab', 'nsclc', 'biomarker', 'amivantamab']
 keynote-789: p-chemo + pembro in osi resistant egfr-mutant nsclc pfs &amp; os pd-l1 not a biomarker here
again, a negative trial in this setting.
bispecific mab (amivantamab), adc (e.g. patritumab) and tkis are the ways to follow targeting egfr resistance #asco23 
MD PhD, lung oncologist & researcher @IEOufficiale; @myESMO Communication Committee Chair; #LungCancer Molecular target-believer #LCSM